Skip to main content
SpringerLink
Log in

Hepatotoxicity with tocilizumab: Canadian and NZ warnings

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. PY = patient years

References

  1. Health Canada. Important Safety Information on ACTEMRA (tocilizumab) - Risk of Hepatotoxicity. Internet Document : 21 May 2019. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69991a-eng.php

  2. Campbell J. IMPORTANT SAFETY UPDATE - ACTEMRA (tocilizumab). A new important identified risk: Hepatoxicity. Internet Document : [3 pages], 7 May 2019. Available from: URL: https://medsafe.govt.nz/safety/DHCPLetters/ActemraMay2019.pdf

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hepatotoxicity with tocilizumab: Canadian and NZ warnings. Reactions Weekly 1755, 2 (2019). https://doi.org/10.1007/s40278-019-62556-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-62556-8

Search

Navigation